BeyondSpring Inc. announced new post-hoc analyses from its global Phase 3 DUBLIN-3 Study, evaluating Plinabulin in combination with docetaxel for patients with EGFR wild-type non-squamous non-small cell lung cancer (NSCLC) who have progressed after anti-PD-$(L)$1 immunotherapy. The results, presented at the 2025 IASLC/ASCO North America Conference on Lung Cancer (NACLC), showed that the combination of Plinabulin and docetaxel provided clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone. Specifically, median overall survival was 15.8 months for the combination versus 11.7 months for docetaxel alone, with a hazard ratio of 0.55. Median progression-free survival was 5.6 months versus 3.8 months (HR=0.67), and the objective response rate was 18.2% versus 8.0%. The company also reported reductions in brain metastasis and a substantial improvement in metastasis-free survival. BeyondSpring plans to initiate the global Phase 3 DUBLIN-4 trial as a confirmatory study to support a future new drug application.